ELEDON PHARMACEUTICALS
(NASDAQ: ELDN)

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.

4.650

+0.460 (+10.98%)
Range 3.950 - 4.760   (20.51%)
Open 4.070
Previous Close 4.190
Bid Price 2.080
Bid Volume 8
Ask Price 2.150
Ask Volume 9
Volume 1,001,330
Value -
Remark
Delayed prices. Updated at 01 Nov 2024 04:00.
Data powered by
View All Events

Loading Chart...

Please login to view stock data and analysis